Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Cancers (Basel). 2020 Mar 6;12(3):617. doi: 10.3390/cancers12030617. Cancers (Basel). 2020. PMID: 32155941 Free PMC article.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Breast Cancer Res. 2020 Apr 6;22(1):33. doi: 10.1186/s13058-020-01271-0. Breast Cancer Res. 2020. PMID: 32252811 Free PMC article. Review.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: bianchi gv. Cancers (Basel). 2021 Apr 19;13(8):1964. doi: 10.3390/cancers13081964. Cancers (Basel). 2021. PMID: 33921727 Free PMC article.
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Sirico M, et al. Among authors: bianchi gv. Cancers (Basel). 2020 Nov 10;12(11):3314. doi: 10.3390/cancers12113314. Cancers (Basel). 2020. PMID: 33182575 Free PMC article.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Lobefaro R, et al. Among authors: bianchi gv. Ther Adv Med Oncol. 2020 Dec 7;12:1758835920970081. doi: 10.1177/1758835920970081. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33335565 Free PMC article.
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.
Ligorio F, Zambelli L, Bottiglieri A, Castagnoli L, Zattarin E, Lobefaro R, Ottini A, Vingiani A, Pupa SM, Bianchi GV, Capri G, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: bianchi gv. Ther Adv Med Oncol. 2021 Apr 16;13:17588359211006960. doi: 10.1177/17588359211006960. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33948122 Free PMC article.
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin.
Zattarin E, Nichetti F, Ligorio F, Mazzeo L, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, de Braud F, Vernieri C. Zattarin E, et al. Among authors: bianchi gv. Front Oncol. 2022 Aug 18;12:925551. doi: 10.3389/fonc.2022.925551. eCollection 2022. Front Oncol. 2022. PMID: 36059635 Free PMC article.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Among authors: bianchi gv. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.
Di Cosimo S, Appierto V, Silvestri M, Pruneri G, Vingiani A, Perrone F, Busico A, Folli S, Scaperrotta G, de Braud FG, Bianchi GV, Cavalieri S, Daidone MG, Dugo M. Di Cosimo S, et al. Among authors: bianchi gv. Cancers (Basel). 2019 Nov 8;11(11):1753. doi: 10.3390/cancers11111753. Cancers (Basel). 2019. PMID: 31717320 Free PMC article.
79 results